SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2013.
Commission File Number: 001-34949
Tekmira Pharmaceuticals
(Translation of registrant's name into English)
100-8900 Glenlyon Parkway
Burnaby, British Columbia
Canada, V5J 5J8
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ x] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
DOCUMENTS FILED AS PART OF THIS FORM 6-K
See the Exhibit Index hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Tekmira Pharmaceuticals |
||
| Date: May 17, 2013 | By: | /s/ IAN C. MORTIMER |
| Name: | Ian C. Mortimer | |
| Title: | Executive Vice President, Finance and Chief Financial Officer | |
EXHIBIT INDEX
Exhibit
Description
99.1
Press release dated May 17, 2013
EXHIBIT 99.1
Tekmira Announces Election of Directors
VANCOUVER, British Columbia, May 17, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that the nominees listed in the management proxy circular for the 2013 Annual and Special Meeting of Shareholders were elected as directors of Tekmira at the annual meeting held on May 14, 2013 in Vancouver. Detailed results of the vote for the election of directors are set out below:
| Nominee | Votes For | % For | Votes Withheld | % Withheld |
| Michael Abrams | 1,944,876 | 99.25% | 14,740 | 0.75% |
| Kenneth Galbraith | 1,945,046 | 99.26% | 14,570 | 0.74% |
| Don Jewell | 1,945,116 | 99.26% | 14,500 | 0.74% |
| Frank Karbe | 1,942,816 | 99.14% | 16,800 | 0.86% |
| Daniel Kisner | 1,943,276 | 99.17% | 16,340 | 0.83% |
| Mark J. Murray | 1,942,146 | 99.11% | 17,470 | 0.89% |
About Tekmira
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.
CONTACT: Investors
Jodi Regts
Director, Investor Relations
Phone: 604-419-3234
Email: jregts@tekmirapharm.com
Media
David Ryan
Longview Communications Inc.
Phone: 416-649-8007
Email: dryan@longviewcomms.ca